A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A (2012) J Antimicrob Chemother 67: 819-31 NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy. Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE (2014) Antimicrob Agents Chemother 58: 2657-64 High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR (2014) Antimicrob Agents Chemother 58: 3270-5 Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR (2013) Int J Antimicrob Agents 42: 232-7 High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR (2012) J Clin Microbiol 50: 1390-6 Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Osheroff N (2012) Biochemistry 51: 370-81
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.